A comprehensive view of Boehringer Ingelheim GmbH. This page highlights a small sample of our full coverage.
For real-time access, please log in to your Tissue & Hygiene Market Intelligence Service.

Recent Articles

sample of recent headlines, press releases and get more..

Boehringer Ingelheim to downsize US staff and shift to hybrid sales model amid disappointing sales of Humira biosimilar Cyltezo; Boehringer to continue commitment to manufacturing and distribution despite market dominance of AbbVie's original product
Published: April 08, 2024 by FiercePharma
Boehringer Ingelheim and Eli Lilly report results from EMPACT-MI Phase 3 trial of Jardiance (empagliflozin)
Published: April 06, 2024 by Eli Lilly & Co.
Boehringer Ingelheim partners with Shanghai RAAS for the development and clinical production of hemophilia drug SR604 injection; the drug has received approval for Phase I clinical trial targeting hemophilia and congenital factor VII deficiency
Published: March 21, 2024 by Contify Life Science News
AAFA releases statement on asthma inhaler price caps, advocates for change in drug pricing to make medicines more affordable; group lauds Boehringer Ingelheim's US$35 per month cap on out-of-pocket costs for its COPD and asthma inhaler portfolio
Published: March 08, 2024 by GlobeNewswire
Boehringer Ingelheim to cap US patients' out-of-pocket costs for inhaler products at US$35 per month, reduce certain list prices and continue significant discounts to insurers; the move follows criticisms of high inhaler costs by a US Senate committee
Published: March 08, 2024 by FiercePharma

Ask us about our Tissue & Hygiene market view

Trending Chart

Interactive chart with headline count